Comparison of the effects of doxycycline and povidone iodine in treatment of pleural effusion; an open label randomized clinical trial

被引:1
|
作者
Hemmati, Hamid Reza [1 ]
Hadjizadeh, Armin [1 ]
Malek, Farhad [2 ]
Ghorbani, Raheb [3 ]
Zahmatkesh, Mehrdad [4 ]
Soltani, Setareh [1 ]
机构
[1] Semnan Univ Med Sci, Dept Surg, Semnan, Iran
[2] Semnan Univ Med Sci, Dept Internal Med, Semnan, Iran
[3] Semnan Univ Med Sci, Social Determinants Hlth Res Ctr, Semnan, Iran
[4] Semnan Univ Med Sci, Nursing Care Res Ctr, Semnan, Iran
来源
IMMUNOPATHOLOGIA PERSA | 2024年 / 10卷 / 02期
关键词
Pleurodesis; Povidone iodine; Doxycycline; Malignant pleural effusion; IODOPOVIDONE PLEURODESIS; EFFICACY; SAFETY; BLEOMYCIN;
D O I
10.34172/ipp.2022.13186
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Doxycycline is commonly used in treating pleural effusion. Povidone-iodine is another agent that has been used for treating pleural effusion. Objectives: We aimed to compare the effects of doxycycline and povidone iodine in treating pleural effusion. Patients and Methods: Forty-one patients with pleural effusion were enrolled and randomly divided into two groups. After insertion of the chest tube, pleurodesis was performed in the first group with povidone iodine and doxycycline in the second group. The chest tube clamped and opened one hour later. Then, connected to the suction through a double chest bottle. By decreasing of drainage to less than 50 cc per day, the chest tube was removed and the patients were evaluated three days later for pain, fever, empyema, recurrent effusion and long-term side effects at 7(th), 30(th), 60(th) and 90(th) day. Results: The pain intensity was not different between two groups (P > 0.05). None of the patients had empyema and other side effects including hemothorax or pneumothorax were not seen too. In a 90-day follow-up, 47.6% of doxycycline recipients and 25% of povidone iodine recipients experienced the recurrent effusion (P = 0.133). Three patients had fever (one on the first day and two on the second day) in the doxycycline group, while fever was not observed in povidone iodine recipients. The cost of treatment in both groups was almost the same. Conclusion: Side effects of pleurodesis include pain, fever, recurrent effusion, cost in the two groups is almost equal, and both agents can be used as an effective drug for treating pleural effusion.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Efficacy of povidone-iodine nasal rinse and mouth wash in COVID-19 management: a prospective, randomized pilot clinical trial (povidone-iodine in COVID-19 management)
    Alsaleh, Saad
    Alhussien, Ahmed
    Alyamani, Abduljabbar
    Alhussain, Fahad
    Alhijji, Ali
    Binkhamis, Khalifa
    Khan, Anas
    Javer, Amin
    Alshahrani, Fatimah S.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [42] Comparison of Oral Azathioprine and Oral Mini Pulse Steroid in the Treatment of Vitiligo: An Open-Label Randomized Controlled Trial
    Jawade, Sugat
    Saoji, Vikrant
    Madke, Bhushan
    Singh, Adarshlata
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (06) : 591 - 597
  • [43] Full-mouth ultrasonic debridement associated with povidone iodine rinsing in GAgP treatment: a randomised clinical trial
    do Vale, Hugo Felipe
    Viana Casarin, Renato Corra
    Taiete, Tiago
    Bovi Ambrosano, Glaucia Maria
    Silverio Ruiz, Karina Gonzales
    Nociti, Francisco Humberto, Jr.
    Sallum, Enilson Antnio
    Casati, Marcio Zaffalon
    CLINICAL ORAL INVESTIGATIONS, 2016, 20 (01) : 141 - 150
  • [44] Full-mouth ultrasonic debridement associated with povidone iodine rinsing in GAgP treatment: a randomised clinical trial
    Hugo Felipe do Vale
    Renato Corrêa Viana Casarin
    Tiago Taiete
    Gláucia Maria Bovi Ambrosano
    Karina Gonzales Silvério Ruiz
    Francisco Humberto Nociti
    Enílson Antônio Sallum
    Márcio Zaffalon Casati
    Clinical Oral Investigations, 2016, 20 : 141 - 150
  • [45] Evaluating the effect of gargling with hydrogen peroxide and povidone-iodine on salivary viral load of SARS-CoV-2: A pilot randomized clinical trial
    Adl, A.
    Sedigh-Shams, M.
    Jamalidoust, M.
    Rajabzadeh, Z.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2023, 26 (04) : 391 - 396
  • [46] Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
    Tehrani, Shabnam
    Yadegarynia, Davood
    Bagherzade, Afshin
    Gachkar, Latif
    Keyvanfar, Amirreza
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2022, 11
  • [47] Evaluation of the antiseptic activity of 5% alcoholic povidone-iodine solution using four different modes of application: a randomized open-label study
    Monstrey, S. J.
    Lepelletier, D.
    Simon, A.
    Touati, G.
    Vogt, S.
    Favalli, F.
    JOURNAL OF HOSPITAL INFECTION, 2022, 123 : 67 - 73
  • [48] A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
    Ribeiro Sampaio, Raimunda Nonata
    Fontenele e Silva, Juliana Saboia
    Ribeiro de Paula, Carmen Dea
    Porte, Claudia
    Carneiro da Motta, Jorgeth de Oliveira
    de Araujo Pereira, Ledice Inacia
    Martins, Sofia Sates
    Barroso, Daniel Holanda
    Magalhaes Freire, Gustavo Subtil
    Gomes, Ciro Martins
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2019, 52
  • [49] Chlorhexidine-alcohol compared with povidone-iodine-alcohol skin antisepsis protocols in major cardiac surgery: a randomized clinical trial
    Boisson, Matthieu
    Allain, Geraldine
    Roussel, Jean-Christian
    d'Ostrevy, Nicolas
    Burbassi, Silvia
    Demondion, Pierre
    Mertes, Paul-Michel
    Labaste, Francois
    Kerforne, Thomas
    Rozec, Bertrand
    Eljezi, Vedat
    Zannis, Konstantinos
    Leprince, Pascal
    Oulehri, Walid
    Minville, Vincent
    Seguin, Sabrina
    Loiodice, Ambre
    Ruckly, Stephane
    Lucet, Jean-Christophe
    Timsit, Jean-Francois
    Mimoz, Olivier
    INTENSIVE CARE MEDICINE, 2024, : 2114 - 2124
  • [50] A single dose of doxycycline after an ixodes ricinus tick bite to prevent Lyme borreliosis: An open-label randomized controlled trial
    Harms, M. G.
    Hofhuis, A.
    Sprong, H.
    Bennema, S. C.
    Ferreira, J. A.
    Fonville, M.
    van Leeuwen, A. Docters
    Assendelft, W. J. J.
    Van Weert, H. C. P. M.
    Van Pelt, W.
    Van den Wijngaard, C. C.
    JOURNAL OF INFECTION, 2021, 82 (01) : 98 - 104